Amneal introduces generic versions of four popular drugs
BRIDGEWATER, N.J. — Generic drug maker Amneal has introduced four new drugs to the market, all available in tablet form.
The products, approved by the Food and Drug Administration, include:
Lorazepam tablets, a generic version of anxiety treatment Ativan, are available in 0.5-mg, 1-mg and 2-mg strengths, each offered in 100-, 500- and 1,000-count containers;
Meclizine HCl tablets, a generic version of antihistamine Antivert, are available in 12.5-mg and 25-mg strengths in 100-, 500- and 1,000-count bottles;
Promethazine HCl tablets, the generic equivalent of antihistamine Phenergan, are available in strengths of 12.5 mg in 100-count, 25 mg in 100- and 1,000-count and 50 mg in 100-count bottles; and
Venlafaxine HCl tablets, the generic equivalent of antidepressant Effexor, are available in five strengths: 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg, each in a 90-count bottle.
"We are very pleased with the addition of these four new products to Amneal’s portfolio and our continued aggressive growth," Amneal president Chirag Patel said. "Going forward, the pace will accelerate as we add several new dosage forms, introduce complex and unique products and realize the results of our dramatically expanded [research and development] team."
FDA gives tentative approval to Intelliject device
RICHMOND, Va. — The Food and Drug Administration has given tentative approval to an emergency treatment for severe allergic reactions made by Intelliject, the drug maker said.
The FDA granted the tentative approval to e-cue, an epinephrine auto-injector for allergic reactions, including anaphylaxis. Tentative approval means that a product meets the agency’s conditions for final approval but outside issues prevent it from hitting the market. In this case, King Pharmaceuticals and Meridian Medical Technologies have filed a patent infringement suit against Intelliject, alleging that it infringes on its patent for the EpiPen, also an auto-injector used for allergic reactions.
The company said it was confident the dispute with King and Meridian would be "favorably resolved."
Consumer spending down in June
WASHINGTON — Consumer spending for June dropped 0.2% to $21.9 billion, the Commerce Department announced Tuesday.
The drop in consumer spending marked the first decline seen since September 2009.
Meanwhile, personal income was virtually flat, increasing 0.1% to $18.7 billion for the month, which was in line with estimates.
“Today’s personal income data shows that consumers had a little more money in their pockets in June, as incomes increased and prices – particularly gas prices – dropped,” Commerce Department chief economist Mark Doms said. “With an agreement to raise the debt ceiling and avoid default in place, business and consumer confidence is more likely to strengthen, raising the outlook for greater economic growth and job creation in the third quarter.”